Development of an affinity-enhanced clinical candidate TCR targeting NY-ESO-1 with optimal potency and high specificity
Y. Ou, M. Liu, K. Zhan…·S. Zhong
This study develops a high-affinity, specific TCR targeting NY-ESO-1 through engineering and screening, showing efficacy in tumor models and approval for clinical trials.